Concordance between Tramadol and Dextromethorphan Parent/Metabolite Ratios: The Influence of CYP2D6 and Non‐CYP2D6 Pathways on Biotransformation
Authors:
- 1 January 2002
- journal article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 42 (1) , 24-29
Abstract
Cytochrome P4502D6 (CYP2D6) activity has been shown to be a determinant of both the pharmacokinetics and pharmacodynamics of tramadol in adults. This study evaluated the association between CYP2D6 activity, as determined by dextromethorphan (DM) urinary metabolite ratio, and tramadol biotransformation in 13 children (7–16 years). CYP2D6 genotype was determined by XL‐PCR and PCR/RFLP. Phenotype was assessed by HPLC quantitation of DM and its metabolites from a 12‐ to 24‐hour urine collection following a single oral dose of DM. There was only a modest correlation between tramadol/M1 (metabolite 1)plasma concentration or AUC and the DM/dextrorphan (DX) urinary molar ratio in the study cohort; however, when subjects were segregated based on the number of functional CYP2D6 alleles, a much stronger relationship was observed for subjects with two functional alleles, with essentially no relationship evident in those individuals with one functional allele. Further evaluation of these data suggested that the CYP2D6‐mediated metabolite (M1) is formed to a lesser extent, and the formation of the non‐CYP2D6 product (M2) is more pronounced in subjects with one versus two functional alleles. Thus, the number of functional CYP2D6 alleles and the availability of alternative cytochromes P450 capable of metabolizing tramadol may explain the poor association between DM, a well‐characterized CYP2D6 probe, and tramadol in a population of CYP2D6 extensive metabolizers.Keywords
This publication has 16 references indexed in Scilit:
- Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trialPharmacogenetics, 2000
- Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency dataPharmacogenetics, 1999
- Decreased capacity for debrisoquine metabolism among black TanzaniansPharmacogenetics, 1999
- Investigation of terbinafine as a CYP2D6 inhibitor in vivoClinical Pharmacology & Therapeutics, 1999
- Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3AJournal of Pharmacy and Pharmacology, 1998
- Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German populationPharmacogenetics, 1998
- Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective studyEuropean Journal of Clinical Pharmacology, 1997
- The hypoalgesic effect of tramadol in relation to CYP2D6*Clinical Pharmacology & Therapeutics, 1996
- Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylationClinical Pharmacology & Therapeutics, 1985
- Dissociation of co-regulatory control of debrisoquin/phenformin and sparteine oxidation in GhanaiansClinical Pharmacology & Therapeutics, 1985